The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta‐analytic evaluation of recent meta‐analyses
Top Cited Papers
Open Access
- 11 January 2022
- journal article
- review article
- Published by Wiley in World Psychiatry
- Vol. 21 (1), 133-145
- https://doi.org/10.1002/wps.20941
Abstract
Mental disorders represent a worldwide public health concern. Psychotherapies and pharmacotherapies are recommended as first line treatments. However, evidence has emerged that their efficacy may be overestimated, due to a variety of shortcomings in clinical trials (e.g., publication bias, weak control conditions such as waiting list). We performed an umbrella review of recent meta-analyses of randomized controlled trials (RCTs) of psychotherapies and pharmacotherapies for the main mental disorders in adults. We selected meta-analyses that formally assessed risk of bias or quality of studies, excluded weak comparators, and used effect sizes for target symptoms as primary outcome. We searched PubMed and PsycINFO and individual records of the Cochrane Library for meta-analyses published between January 2014 and March 2021 comparing psychotherapies or pharmacotherapies with placebo or treatment-as-usual (TAU), or psychotherapies vs. pharmacotherapies head-to-head, or the combination of psychotherapy with pharmacotherapy to either monotherapy. One hundred and two meta-analyses, encompassing 3,782 RCTs and 650,514 patients, were included, covering depressive disorders, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, somatoform disorders, eating disorders, attention-deficit/hyperactivity disorder, substance use disorders, insomnia, schizophrenia spectrum disorders, and bipolar disorder. Across disorders and treatments, the majority of effect sizes for target symptoms were small. A random effect meta-analytic evaluation of the effect sizes reported by the largest meta-analyses per disorder yielded a standardized mean difference (SMD) of 0.34 (95% CI: 0.26-0.42) for psychotherapies and 0.36 (95% CI: 0.32-0.41) for pharmacotherapies compared with placebo or TAU. The SMD for head-to-head comparisons of psychotherapies vs. pharmacotherapies was 0.11 (95% CI: –0.05 to 0.26). The SMD for the combined treatment compared with either monotherapy was 0.31 (95% CI: 0.19-0.44). Risk of bias was often high. After more than half a century of research, thousands of RCTs and millions of invested funds, the effect sizes of psychotherapies and pharmacotherapies for mental disorders are limited, suggesting a ceiling effect for treatment research as presently conducted. A paradigm shift in research seems to be required to achieve further progress.Keywords
This publication has 165 references indexed in Scilit:
- Conform and be fundedNature, 2012
- Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analysesThe British Journal of Psychiatry, 2012
- Health‐Led Interventions in the Early Years to Enhance Infant and Maternal Mental Health: A Review of ReviewsChild and Adolescent Mental Health, 2010
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyThe New England Journal of Medicine, 2008
- Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?Philosophy, Ethics, and Humanities in Medicine, 2008
- The cost of dichotomising continuous variablesBMJ, 2006
- Why Most Published Research Findings Are FalsePLoS Medicine, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Measurement of health status: Ascertaining the minimal clinically important differenceControlled Clinical Trials, 1989